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1. INTRODUCTION {#jgm3114-sec-0005}
===============

As the third most commonly diagnosed cancer, colorectal cancer (CRC) has a worldwide incidence of over 1.3 million and a mortality rate of approximately 50%.[1](#jgm3114-bib-0001){ref-type="ref"}, [2](#jgm3114-bib-0002){ref-type="ref"}, [3](#jgm3114-bib-0003){ref-type="ref"} Although the incidence of CRC has decreased in recent years because of improvements in its early diagnosis and treatment,[1](#jgm3114-bib-0001){ref-type="ref"} the number of CRC cases continues to increase worldwide. Despite recent advances in treatment modalities, the 5‐year survival rate of patients with advanced CRC is not satisfactory as a result of recurrence and drug resistance.[4](#jgm3114-bib-0004){ref-type="ref"}

Methylenetetrahydrofolate reductase (MTHFR) is required for folate metabolism, intracellular homeostasis and DNA synthesis. It converts 5,10‐methylenetetrahydrofolate (5,10‐MTHF) to 5‐methyltetrahydrofolate (5‐MTHF), which is the major circulating form of folate in the blood and provides methyl groups to convert homocysteine into methionine. MTHFR contributes to the imbalance in methylation reactions, leading to genomic DNA hypomethylation, and influences folate metabolism.[5](#jgm3114-bib-0005){ref-type="ref"}, [6](#jgm3114-bib-0006){ref-type="ref"}

The two most common loci for *MTHFR* single nucleotide polymorphisms (SNPs) are rs1801133 (C677T) and rs1801131 (A1298C).[7](#jgm3114-bib-0007){ref-type="ref"} Both are associated with a deficiency in enzymatic activity.[8](#jgm3114-bib-0008){ref-type="ref"} The *MTHFR* rs1801133 polymorphism is a point mutation at the position 677C\>T, in which alanine is replaced with valine.[9](#jgm3114-bib-0009){ref-type="ref"} The *MTHFR* rs1801131 polymorphism is a point mutation at position 1298A\>C, in which glutamate is replaced with valine.[10](#jgm3114-bib-0010){ref-type="ref"} The rs1801133 and rs1801131 polymorphisms reduce the activity of the MTHFR enzyme and increase the homocysteine level in the blood, which may be a risk factor for cancer.[11](#jgm3114-bib-0011){ref-type="ref"}

Recently, some meta‐analyses have reported significant correlations between the *MTHFR* rs1801133 and rs1801131 polymorphisms and tumour responses to chemoradiotherapy and short‐term clinical benefits.[12](#jgm3114-bib-0012){ref-type="ref"}, [13](#jgm3114-bib-0013){ref-type="ref"}, [14](#jgm3114-bib-0014){ref-type="ref"} For example, two meta‐analyses were performed to investigate the associations between *MTHFR* polymorphisms and the response of patients with CRC to chemotherapy.[13](#jgm3114-bib-0013){ref-type="ref"}, [14](#jgm3114-bib-0014){ref-type="ref"} A meta‐analysis was conducted to investigate the associations between *MTHFR* polymorphisms and short‐term clinical benefits (complete or partial response, relapse or progression) of chemotherapy in patients with CRC.[12](#jgm3114-bib-0012){ref-type="ref"} These meta‐analyses only focused on the short‐term prognostic effects of *MTHFR* polymorphisms on patients with CRC.

No meta‐analysis has been performed investigating the association between these *MTHFR* polymorphisms and survival (e.g. overall survival \[OS\], progression‐free survival \[PFS\] or disease‐free survival \[DFS\]). By systematically reviewing recent publications, we conducted a meta‐analysis according to the guidelines of the PRISMA statement.[15](#jgm3114-bib-0015){ref-type="ref"} The aim was to explore whether the *MTHFR* rs1801133 and rs1801131 polymorphisms might affect the prognosis of patients with CRC and whether these SNPs are potentially useful as predictive biomarkers.

2. MATERIALS AND METHODS {#jgm3114-sec-0006}
========================

2.1. Literature search strategy {#jgm3114-sec-0007}
-------------------------------

A comprehensive literature search was performed independently by two investigators (XLC and YMW) from the inception of each database up to 14 March 2016. The databases included PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and Chinese databases (including CNKI, Wanfang and VIP). The search terms included the keywords: colorectal cancer (including colorectal cancer, colon cancer, rectal cancer), MTHFR (including MTHFR and methylenetetrahydrofolate reductase) and prognosis (including prognosis, prognoses, predictive, biomarker, marker, survival, log rank, Kaplan--Meier and Cox). The detailed search strategy is documented in the Supporting information ([Doc. S1](#jgm3114-supitem-0001){ref-type="supplementary-material"}). Google Scholar was also used to search for relevant articles. Systematic reviews and meta‐analyses of *MTHFR* polymorphisms and CRC were manually screened for potentially eligible articles.

Duplicate articles that were obtained from multiple databases were deleted. The abstract of each article was extracted and screened by two of three investigators (FZ, TGY and GT), and the full texts of potentially eligible articles were reviewed for data analysis. Next, two of three investigators (FZ, TGY and GT) independently reviewed and confirmed the eligibility of the articles. Any disagreement was recorded and resolved by consensus under the guidance of a fourth investigator (XLC). The cross‐referencing strategy was adopted until the two investigators reached a consistent result.

2.2. Inclusion criteria for the studies {#jgm3114-sec-0008}
---------------------------------------

This meta‐analysis includes articles reporting the patient\'s CRC prognosis and *MTHFR* genotype. The inclusion criteria comprised: (i) a diagnosis of CRC, colon cancer, rectal cancer or metastatic CRC (mCRC); (ii) rs1801133 or rs1801131 polymorphisms identified by polymerase chain reaction (PCR) or polymerase chain reaction restriction fragment length polymorphism (PCR‐RFLP); and (iii) data describing OS, DFS and/or PFS with hazard ratios (HRs), 95% confidence intervals (CIs) or the relevant information (e.g. survival curves) were provided. Articles published in abstract form were included only when sufficient outcome data were presented or when the authors were willing to provide detailed results from the study. If several articles from the same patient population were reported, the most recent or most detailed study was included.

2.3. Data extraction and quality assessment {#jgm3114-sec-0009}
-------------------------------------------

For each article, two of three investigators (FZ, TGY and GT) independently extracted the required data according to a predefined protocol. The extracted data comprised: authors' names, year of publication, patient characteristics (cancer type, sample size, gender and mean age), therapy (surgery, chemotherapy and radiotherapy), characteristics of *MTHFR* polymorphisms (rs1801133 or rs1801131, sample source, sample content, test method and cut‐off values) and prognostic outcomes (HRs and their 95% CIs for OS, PFS and DFS). If the data from any of the above categories were unavailable in the text, the corresponding record was marked as "NR (not reported)". Differences in data extraction were resolved by cross‐checking until a consensus was reached.

2.4. Statistical analysis {#jgm3114-sec-0010}
-------------------------

Four genetic models existed for rs1801133: TT versus CC (TT/CC, additive model), TT versus CT and CC (TT/CT + CC, recessive model), TT and CT versus CC (TT + CT/CC, dominant model) and CT versus CC (CT/CC, heterozygous model). For rs1801131, the four models included CC versus AA (CC/AA), CC versus CA and AA (CC/CA + AA), CC and CA versus AA (CC + CA/AA) and CA versus AA (CA/AA). None of the included articles reported data about the allele model (wild‐type allele versus mutant‐type allele) for rs1801133 and rs1801131. Therefore, the allele model was not included in our meta‐analysis. OS, PFS and DFS were analysed separately.

The HRs and 95% CIs reflected the effects of rs1801133 and rs1801131 on the prognosis. If these data were available in the collected articles, we extracted these data directly; otherwise, they were calculated from the available numerical data in the articles based on the methods developed by Tierney *et al*.[16](#jgm3114-bib-0016){ref-type="ref"}

Pooled HRs and their 95% CIs for OS, PFS and DFS between different genetic models were calculated. The heterogeneity of all HRs was calculated using chi‐squared tests. The heterogeneity test with the inconsistency index (*I* ^2^) statistic and *Q* statistic was performed. If the HR was homogeneous, then the fixed‐effects model was employed for analysis; otherwise, a random‐effects model was used. *p* \< 0.05 was considered statistically significant. Additionally, an HR \> 1 suggested a poor prognosis. Publication bias was evaluated using the methods described by Begg and Mazumdar.[17](#jgm3114-bib-0017){ref-type="ref"}

Linkage disequilibrium among the variants can vary across populations.[18](#jgm3114-bib-0018){ref-type="ref"}, [19](#jgm3114-bib-0019){ref-type="ref"} For example, Haerian and Haerian[18](#jgm3114-bib-0018){ref-type="ref"} showed that rs1801133 and rs1801131 might be CRC susceptibility variants in Americans and Australians, whereas rs1801133 may be more common in the Brazilian and Japanese populations. Based on these results, patients of different ethnicities may carry different rs1801133 and rs1801131 variants. Therefore, a subgroup analysis based on different regions (e.g. Asia and Western countries) was performed. All calculations were performed using STATA, version 12.0 (StataCorp, College Station, TX, USA).

3. RESULTS {#jgm3114-sec-0011}
==========

3.1. Article characteristics {#jgm3114-sec-0012}
----------------------------

Figure [1](#jgm3114-fig-0001){ref-type="fig"} shows the process used to screen the included articles. The literature search yielded 539 articles, 152 of which were excluded as a result of duplication. The abstracts of 387 articles were reviewed by the investigators, and the 314 articles that failed to meet the inclusion criteria were excluded. The full texts of the remaining 73 articles were retrieved. Finally, twenty‐four articles were included in the meta‐analysis.[20](#jgm3114-bib-0020){ref-type="ref"}, [21](#jgm3114-bib-0021){ref-type="ref"}, [22](#jgm3114-bib-0022){ref-type="ref"}, [23](#jgm3114-bib-0023){ref-type="ref"}, [24](#jgm3114-bib-0024){ref-type="ref"}, [25](#jgm3114-bib-0025){ref-type="ref"}, [26](#jgm3114-bib-0026){ref-type="ref"}, [27](#jgm3114-bib-0027){ref-type="ref"}, [28](#jgm3114-bib-0028){ref-type="ref"}, [29](#jgm3114-bib-0029){ref-type="ref"}, [30](#jgm3114-bib-0030){ref-type="ref"}, [31](#jgm3114-bib-0031){ref-type="ref"}, [32](#jgm3114-bib-0032){ref-type="ref"}, [33](#jgm3114-bib-0033){ref-type="ref"}, [34](#jgm3114-bib-0034){ref-type="ref"}, [35](#jgm3114-bib-0035){ref-type="ref"}, [36](#jgm3114-bib-0036){ref-type="ref"}, [37](#jgm3114-bib-0037){ref-type="ref"}, [38](#jgm3114-bib-0038){ref-type="ref"}, [39](#jgm3114-bib-0039){ref-type="ref"}, [40](#jgm3114-bib-0040){ref-type="ref"}, [41](#jgm3114-bib-0041){ref-type="ref"}, [42](#jgm3114-bib-0042){ref-type="ref"}, [43](#jgm3114-bib-0043){ref-type="ref"}

![Flow chart of the search strategy](JGM-21-na-g001){#jgm3114-fig-0001}

Table [1](#jgm3114-tbl-0001){ref-type="table"} summarizes the characteristics of the included articles. Among the 24 included articles, seven were conducted in China or Korea,[20](#jgm3114-bib-0020){ref-type="ref"}, [24](#jgm3114-bib-0024){ref-type="ref"}, [26](#jgm3114-bib-0026){ref-type="ref"}, [28](#jgm3114-bib-0028){ref-type="ref"}, [31](#jgm3114-bib-0031){ref-type="ref"}, [32](#jgm3114-bib-0032){ref-type="ref"}, [42](#jgm3114-bib-0042){ref-type="ref"} one was conducted in Mexico[33](#jgm3114-bib-0033){ref-type="ref"} and the remaining articles were conducted in European or North American countries. All but two eligible articles targeted CRC or mCRC: one addressed rectal cancer[22](#jgm3114-bib-0022){ref-type="ref"} and the other studied colon cancer.[28](#jgm3114-bib-0028){ref-type="ref"} In total, 5423 patients with CRC were included in our analysis. The sample size of each article ranged from 29 to 784 patients, with a median of 136 patients. All patients received either 5‐fluorouracil (5‐FU) or 5‐FU‐based chemotherapy. Information about the rs1801133 and rs1801131 polymorphisms is provided in Table [2](#jgm3114-tbl-0002){ref-type="table"}.

###### 

Characteristics of the included articles

  Reference                                                            Year of publication   Country     Time         Patients        Sample size   Number of males   Mean age (range, years)   Stage                                         Surgery   Chemotherapy               Radiotherapy   Median (range) follow‐up (months)
  -------------------------------------------------------------------- --------------------- ----------- ------------ --------------- ------------- ----------------- ------------------------- --------------------------------------------- --------- -------------------------- -------------- -----------------------------------
  Afzal *et al*.[36](#jgm3114-bib-0036){ref-type="ref"}                2009                  Denmark     1996--2003   CRC             331           166               61 (NR)                   II--IV                                        NR        5‐FU + LV                  NR             120 (NR)
  Budai *et al*.[29](#jgm3114-bib-0029){ref-type="ref"}                2012                  Hungary     2006--2008   CRC             85            NR                NR (NR)                   IV                                            NR        5‐FU + LV + CPT‐11 + BEV   NR             NR (NR)
  Castillo‐Fernández *et al*.[33](#jgm3114-bib-0033){ref-type="ref"}   2010                  Mexico      1998--2004   mCRC            29            11                55.9 (NR)                 IV                                            NR        5‐FU + FA                  NR             NR (NR)
  Cecchin *et al*.[21](#jgm3114-bib-0021){ref-type="ref"}              2015                  Italy       2003--2007   CRC             112           62                65 (30--85)               II, III                                       All       5‐FU/CAPE                  NR             80 (10--185)
  Chua *et al*.[37](#jgm3114-bib-0037){ref-type="ref"}                 2009                  Britain     1999--2000   mCRC            118           80                61 (31--75)               IV                                            NR        5‐FU + LV + OX             NR             NR (NR)
  Custodio *et al*.[23](#jgm3114-bib-0023){ref-type="ref"}             2014                  Spain       2004--2009   CRC             202           115               63.8 (23--85)             II, III                                       All       5‐FL + OX                  None           51.4 (7--96)
  Delgado‐Plasencia *et al*.[27](#jgm3114-bib-0027){ref-type="ref"}    2013                  Spain       1990--2003   CRC             50            28                NR (NR)                   NR                                            All       5‐FU‐based                 NR             NR (NR)
  Dong *et al*.[20](#jgm3114-bib-0020){ref-type="ref"}                 2016                  China       2012--2013   CRC             81            44                56.2 (27--76)             IV                                            NR        5‐FU + LV + OX             NR             14 (5--20)
  Etienne *et al*.[43](#jgm3114-bib-0043){ref-type="ref"}              2004                  France      NR           mCRC            98            57                64 (40--82)               IV                                            NR        5FU + FA                   NR             NR (NR)
  Fernández‐Peralta *et al*.[34](#jgm3114-bib-0034){ref-type="ref"}    2010                  Spain       1992--1996   CRC             143           81                67.3 (NR)                 NR                                            All       5‐FU‐based                 NR             44.3 (NR)
  Gusella *et al*.[35](#jgm3114-bib-0035){ref-type="ref"}              2009                  Britain     1999--2008   CRC             130           84                64.7 (34--84)             B, C[\*](#jgm3114-note-0002){ref-type="fn"}   NR        5‐FU + LV                  NR             45.6 (4.8--120.0)
  Huang *et al*.[31](#jgm3114-bib-0031){ref-type="ref"}                2011                  China       2005--2009   mCRC            157           85                62.5 (36--82)             IV                                            NR        5‐FU + LV + OX             NR             35 (8--56)
  Jang *et al*.[24](#jgm3114-bib-0024){ref-type="ref"}                 2014                  Korea       1996--2009   CRC             372           215               62.1 (NR)                 I--IV                                         All       5‐FU‐based                 NR             34 (4--173)
  Kim *et al*.[32](#jgm3114-bib-0032){ref-type="ref"}                  2010                  Korea       1995--2004   CRC             103           49                57.0 (NR)                 II--IV                                        All       5‐FU/5‐FU + OX             NR             62.2 (18--121)
  Negandhi *et al*.[25](#jgm3114-bib-0025){ref-type="ref"}             2013                  Canada      1999--2003   CRC             784           327               61.4 (20.7--75.0)         I--IV                                         All       5‐FU (partial)             NR             76.8 (4.8--130.8)
  Qiu *et al*.[28](#jgm3114-bib-0028){ref-type="ref"}                  2013                  China       2004--2006   CRC             76            48                57 (21--75)               I--III                                        All       5‐FU + OX + LV             NR             NR (37--67)
  Ruzzo *et al*.[40](#jgm3114-bib-0040){ref-type="ref"}                2007                  Italy       NR           mCRC            166           87                66 (NR)                   IV                                            NR        5‐FU + LV + OX             NR             24 (NR)
  Ruzzo *et al*.[39](#jgm3114-bib-0039){ref-type="ref"}                2008                  Italy       NR           mCRC            146           80                61 (38--75)               IV                                            NR        5‐FU + LV + CPT‐11         NR             NR (NR)
  Sharma *et al*.[38](#jgm3114-bib-0038){ref-type="ref"}               2008                  Australia   2002--2003   mCRC            54            35                72 (42--86)               IV                                            NR        CAPE                       NR             NR (NR)
  Suh *et al*.[42](#jgm3114-bib-0042){ref-type="ref"}                  2006                  Korea       NR           mCRC            54            30                57.8 (35--39)             II--IV                                        NR        5‐FU + LV + OX             NR             23.6 (6--35)
  Taflin *et al*.[30](#jgm3114-bib-0030){ref-type="ref"}               2011                  Sweden      1999--2006   CRC             649           88                66 (32--82)               III                                           All       5‐FU + LV                  NR             70 (NR)
  Ulrich *et al*.[22](#jgm3114-bib-0022){ref-type="ref"}               2014                  America     1994--2000   Rectal cancer   754           482               61 (19--86)               II, III                                       All       5‐FU + LV                  All            NR (NR)
  Zhang *et al*.[41](#jgm3114-bib-0041){ref-type="ref"}                2007                  America     1992--2003   mCRC            318           177               58 (25--86)               IV                                            NR        FU + CPT‐11/FU + OX        NR             30 (NR)
  Zhu *et al*.[26](#jgm3114-bib-0026){ref-type="ref"}                  2013                  China       2004--2007   CRC             411           245               60 (NR)                   I--IV                                         All       5‐FU/5‐FU + OX             NR             64 (1--88)

5‐FU, 5‐fluorouracil; BEV, bevacizumab; CAPE, capecitabine; CPT‐11, irinotecan; CRC, colorectal cancer; FA, folinic acid; FU, fluorouracil; LV, leucovorin; mCRC, metastatic CRC; NR, not reported; OX, oxaliplatin;

, Duke\'s stage.

###### 

Information about and results for the rs1801133 and rs1801131 polymorphisms in the included studies

  Reference                                                            rs1801133   rs1801131   Test sample        Test content   Test method   Analytical method   Outcome reported
  -------------------------------------------------------------------- ----------- ----------- ------------------ -------------- ------------- ------------------- ---------------------------------------------------------------------------------------
  Afzal *et al*.[36](#jgm3114-bib-0036){ref-type="ref"}                Yes         Yes         Tumour tissue      DNA            PCR^\#^       Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}, PFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Budai *et al*.[29](#jgm3114-bib-0029){ref-type="ref"}                Yes         --          Blood              DNA            PCR           Mul                 OS[\^](#jgm3114-note-0005){ref-type="fn"}, PFS[\^](#jgm3114-note-0005){ref-type="fn"}
  Castillo‐Fernández *et al*.[33](#jgm3114-bib-0033){ref-type="ref"}   Yes         --          Tissue             DNA            PCR           Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Cecchin *et al*.[31](#jgm3114-bib-0031){ref-type="ref"}              Yes         Yes         Blood or tissue    DNA            PCR^\#^       Mul                 DFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Chua *et al*.[37](#jgm3114-bib-0037){ref-type="ref"}                 Yes         --          Tissue             DNA            PCR           Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}, PFS[\^](#jgm3114-note-0005){ref-type="fn"}
  Custodio *et al*.[33](#jgm3114-bib-0033){ref-type="ref"}             Yes         --          Tissue             DNA            PCR‐RFLP      Uni                 DFS[\^](#jgm3114-note-0005){ref-type="fn"}
  Delgado‐Plasencia *et al*.[27](#jgm3114-bib-0027){ref-type="ref"}    Yes         --          Tumour tissue      DNA            PCR‐RFLP      Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Dong *et al*.[20](#jgm3114-bib-0020){ref-type="ref"}                 Yes         --          Tissue             DNA            PCR           Uni                 DFS[\^](#jgm3114-note-0005){ref-type="fn"}
  Etienne *et al*.[43](#jgm3114-bib-0043){ref-type="ref"}              Yes         Yes         Tissue             DNA            PCR           Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}
  Fernández‐Peralta *et al*.[34](#jgm3114-bib-0034){ref-type="ref"}    Yes         Yes         Blood and tissue   DNA            PCR           Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}
  Gusella *et al*.[35](#jgm3114-bib-0035){ref-type="ref"}              Yes         Yes         Blood              DNA            PCR           Uni                 OS[\*](#jgm3114-note-0004){ref-type="fn"}, DFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Huang *et al*.[31](#jgm3114-bib-0031){ref-type="ref"}                Yes         --          Blood              DNA            PCR‐RFLP      Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}, PFS[\^](#jgm3114-note-0005){ref-type="fn"}
  Jang *et al*.[24](#jgm3114-bib-0024){ref-type="ref"}                 Yes         Yes         Blood              DNA            PCR           Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}, DFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Kim *et al*.[32](#jgm3114-bib-0032){ref-type="ref"}                  Yes         --          Leukocytes         DNA            PCR‐RFLP      Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Negandhi *et al*.[25](#jgm3114-bib-0025){ref-type="ref"}             --          Yes         Blood              DNA            PCR^\#^       Mul                 OS[&](#jgm3114-note-0006){ref-type="fn"}
  Qiu *et al*.[28](#jgm3114-bib-0028){ref-type="ref"}                  Yes         Yes         Blood              DNA            PCR           Mul                 PFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Ruzzo *et al*.[40](#jgm3114-bib-0040){ref-type="ref"}                Yes         Yes         Blood              DNA            PCR           Mul                 PFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Ruzzo *et al*.[39](#jgm3114-bib-0039){ref-type="ref"}                Yes         Yes         Blood              DNA            PCR           Mul                 PFS[\*](#jgm3114-note-0004){ref-type="fn"}
  Sharma *et al*.[38](#jgm3114-bib-0038){ref-type="ref"}               Yes         --          Blood              DNA            PCR           Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Suh *et al*.[42](#jgm3114-bib-0042){ref-type="ref"}                  Yes         --          Tissue             DNA            PCR           Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Taflin *et al*.[30](#jgm3114-bib-0030){ref-type="ref"}               Yes         --          Blood              DNA            PCR^\#^       Uni                 OS[\^](#jgm3114-note-0005){ref-type="fn"}
  Ulrich *et al*.[22](#jgm3114-bib-0022){ref-type="ref"}               Yes         Yes         Tissue             DNA            PCR^\#^       Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}
  Zhang *et al*.[41](#jgm3114-bib-0041){ref-type="ref"}                Yes         Yes         Blood and tissue   DNA            PCR^\#^       Mul                 OS[\*](#jgm3114-note-0004){ref-type="fn"}
  Zhu *et al*.[26](#jgm3114-bib-0026){ref-type="ref"}                  Yes         Yes         Blood              DNA            PCR\#         Mul                 OS\*

--, Not available;

for both rs1801133 and rs1801131;

for rs1801133 alone;

for rs1801131 alone. PCR, polymerase chain reaction; PCR^\#^, PCR TaqMan; PCR‐RFLP, polymerase chain reaction restriction fragment length polymorphism; Mul, multivariate analysis; Uni, univariate analysis.

3.2. Meta‐analysis of rs1801133 {#jgm3114-sec-0013}
-------------------------------

Twenty‐three of the included articles assessed the association between rs1801133 and survival time. According to the heterogeneity analysis, all of the articles were homogeneous and the fixed‐effect model was adopted. Compared with patients carrying the CC genotype, patients carrying the TT genotype did not show an increased HR for OS (HR = 1.17; 95% CI = 0.99--1.40), PFS (HR = 0.90; 95% CI = 0.70--1.15) or DFS (HR = 1.23; 95% CI = 0.93--1.62) (Table [3](#jgm3114-tbl-0003){ref-type="table"}). Additionally, significant differences in OS (HR = 1.07; 95% CI = 0.76--1.49), PFS (HR = 0.91; 95% CI = 0.53--1.55) and DFS (HR = 1.27; 95% CI = 0.86--1.88) were not observed between patients carrying the TT genotype and patients carrying the CT + CC genotypes (Table [3](#jgm3114-tbl-0003){ref-type="table"}). In the comparison of patients carrying the TT + CT genotypes with patients carrying the CC genotype, the pooled HRs of OS, PFS and DFS were 1.09 (95% CI = 0.90--1.31), 1.12 (95% CI = 0.85--1.48) and 1.02 (95% CI = 0.69--1.51), respectively (Table [3](#jgm3114-tbl-0003){ref-type="table"}). Significant differences in OS, PFS and DFS were not observed between patients carrying the CT genotypes and patients carrying the CC genotypes (Table [3](#jgm3114-tbl-0003){ref-type="table"}).

###### 

Results of the meta‐analysis of the *MTHFR* rs1801133 polymorphism

                   Number of articles   Number of patients   HR (95% CI)         Heterogeneity (*I* ^2^, *p*)
  ---------------- -------------------- -------------------- ------------------- ------------------------------
  **TT/CC**                                                                      
  OS               11                   2,526                1.17 (0.99--1.40)   0.0%, 0.957
  PFS              5                    672                  0.90 (0.70--1.15)   0.0%, 0.778
  DFS              3                    1,256                1.23 (0.93--1.62)   11.1%, 0.325
  **TT/CT + CC**                                                                 
  OS               5                    840                  1.07 (0.76--1.49)   2.1%, 0.395
  PFS              1                    331                  0.91 (0.53--1.55)   --
  DFS              3                    686                  1.27 (0.86--1.88)   34.4%, 0.218
  **TT + CT/CC**                                                                 
  OS               8                    1,574                1.09 (0.90--1.31)   40.9%, 0.106
  PFS              3                    284                  1.12 (0.85--1.48)   52.3%, 0.123
  DFS              2                    448                  1.02 (0.69--1.51)   0.0%, 0.387
  **CT/CC**                                                                      
  OS               10                   2,369                1.12 (0.96--1.31)   0.0%, 0.673
  PFS              2                    203                  0.96 (0.68--1.36)   47.0%, 0.170
  DFS              3                    1,256                1.10 (0.90--1.35)   0.0%, 0.478

TT/CC: TT genotype versus CC genotype; TT/CT + CC: TT genotype versus (CT + CC) genotype; TT + CT/CC: (TT + CT) genotype versus CC genotype; CT/CC: CT genotype versus CC genotype. −, not available.

Subgroup analysis revealed similar results for patients with CRC from Asian regions or Western regions (Table [4](#jgm3114-tbl-0004){ref-type="table"}). For example, the HR of the TT versus CC genotype for patients from Asian regions was 1.06 (95% CI = 0.75--1.49) and the value for patients from Western regions was 1.22 (95% CI = 0.99--1.50).

###### 

Results for the subgroup analysis of the *MTHFR* rs1801133 polymorphism in different geographic regions

                   Subgroup   Number of articles   Number of patients   HR (95% CI)
  ---------------- ---------- -------------------- -------------------- -------------------
  **TT/CC**                                                             
  OS               Asian      4                    994                  1.06 (0.75--1.49)
  Western          7          1,532                1.22 (0.99--1.50)    
  PFS              Asian      1                    157                  1.53 (0.36--6.51)
  Western          4          515                  0.88 (0.68--1.14)    
  DFS              Asian      1                    372                  0.71 (0.33--1.53)
  Western          2          884                  1.33 (0.99--1.79)    
  **TT/CT + CC**                                                        
  OS               Asian      2                    426                  0.94 (0.59--1.51)
  Western          3          414                  1.19 (0.78--1.81)    
  PFS              Asian      --                   --                   --
  Western          1          331                  0.91 (0.53--1.55)    
  DFS              Asian      1                    372                  0.86 (0.45--1.64)
  Western          2          314                  1.59 (0.98--2.58)    
  **TT + CT/CC**                                                        
  OS               Asian      3                    426                  1.13 (0.76--1.69)
  Western          5          995                  1.07 (0.87--1.33)    
  PFS              Asian      1                    81                   1.81 (0.99--3.32)
  Western          2          203                  0.98 (0.72--1.34)    
  DFS              Asian      2                    448                  1.02 (0.69--1.51)
  Western          --         --                   --                   
  **CT/CC**                                                             
  OS               Asian      3                    837                  1.22 (0.89--1.67)
  Western          7          1,532                1.09 (0.92--1.30)    
  PFS              Asian      --                   --                   --
  Western          2          203                  0.96 (0.68--1.36)    
  DFS              Asian      1                    372                  0.89 (0.53--1.50)
  Western          2          884                  1.14 (0.92--1.43)    

--, Not available.

3.3. Meta‐analysis of rs1801131 {#jgm3114-sec-0014}
-------------------------------

Thirteen articles assessed the association between rs1801131 and survival time. Significant differences in OS, PFS and DFS were not observed between patients carrying the CC genotype and patients carrying the AA genotype (Table [5](#jgm3114-tbl-0005){ref-type="table"}). Compared with patients with the CA + AA genotypes, patients with the CC genotype had a shorter OS (HR = 1.85; 95% CI = 1.30--2.65) and DFS (HR = 2.16; 95% CI = 1.19--3.93) (Figure [2](#jgm3114-fig-0002){ref-type="fig"} and Table [5](#jgm3114-tbl-0005){ref-type="table"}). Significant differences in OS, PFS and DFS were not observed between patients with the CC + CA genotypes and patients with the AA genotype (Table [5](#jgm3114-tbl-0005){ref-type="table"}). Significant differences in OS, PFS and DFS were not observed between patients with the CA genotype and patients with the AA genotype (Table [5](#jgm3114-tbl-0005){ref-type="table"}).

###### 

Results of the meta‐analysis of the *MTHFR* rs1801131 polymorphism

                   Number of articles   Number of patients   HR (95% CI)                                                Heterogeneity (*I* ^2^, *p*)
  ---------------- -------------------- -------------------- ---------------------------------------------------------- ------------------------------
  **CC/AA**                                                                                                             
  OS               7                    2,867                1.13 (0.81--1.59)[\*](#jgm3114-note-0010){ref-type="fn"}   50.9%, 0.057
  PFS              2                    312                  0.89 (0.58--1.37)                                          0.0%, 0.660
  DFS              3                    1,256                0.78 (0.53--1.13)                                          0.0%, 0.738
  **CC/CA + AA**                                                                                                        
  OS               3                    1,254                1.85 (1.30--2.65)                                          0.0%, 0.584
  PFS              --                   --                   --                                                         --
  DFS              2                    484                  2.16 (1.19--3.93)                                          0.0%, 0.337
  **CC + CA/AA**                                                                                                        
  OS               5                    1,948                1.11 (0.85--1.45)[\*](#jgm3114-note-0010){ref-type="fn"}   62.3%, 0.031
  PFS              2                    412                  0.79 (0.55--1.14)                                          0.0%, 0.547
  DFS              1                    372                  0.92 (0.55--1.54)                                          --
  **CA/AA**                                                                                                             
  OS               6                    2,549                0.97 (0.84--1.12)                                          0.0%, 0.507
  PFS              2                    312                  0.97 (0.60--1.57)                                          0.0%, 0.933
  DFS              3                    1,256                0.88 (0.73--1.07)                                          0.0%, 0.974

CC/AA: CC genotype versus AA genotype; CC/CA + AA: CC genotype versus (CA + AA) genotype; CC + CA/AA: (CC + CA) genotype versus AA genotype; CA/AA: CA genotype versus AA genotype. −, not available.

Results from the random‐effects model.

![Meta‐analysis plots of the HRs for survival in the comparison of patients with the CC genotype and patients with the AA + CA genotypes of rs1801131. OS, overall survival; PFS, progression‐free survival; DFS, disease‐free survival](JGM-21-na-g002){#jgm3114-fig-0002}

Subgroup analysis revealed similar results for patients with CRC from Asian regions and Western regions (Table [6](#jgm3114-tbl-0006){ref-type="table"}). For example, the HR of the CC versus AA genotype in patients from Asian regions was 0.81 (95% CI = 0.51--1.29) and the HR for this same comparison of patients from Western regions was 1.25 (95% CI = 0.82--1.91).

###### 

Results from the subgroup analysis of the *MTHFR* rs1801131 polymorphism in different geographic regions

                   Subgroup   Number of articles   Number of patients                                         HR (95% CI)
  ---------------- ---------- -------------------- ---------------------------------------------------------- -------------------
  **CC/AA**                                                                                                   
  OS               Asian      2                    783                                                        0.81 (0.51--1.29)
  Western          5          2,084                1.25 (0.82--1.91)[\*](#jgm3114-note-0012){ref-type="fn"}   
  PFS              Asian      --                   --                                                         --
  Western          2          203                  0.89 (0.58--1.37)                                          
  DFS              Asian      1                    372                                                        1.20 (0.37--3.89)
  Western          2          884                  0.74 (0.50--1.10)                                          
  **CC/CA + AA**                                                                                              
  OS               Asian      1                    372                                                        1.13 (0.35--3.65)
  Western          2          882                  1.95 (1.34--2.84)                                          
  PFS              Asian      --                   --                                                         --
  Western          --         --                   --                                                         
  DFS              Asian      1                    372                                                        1.32 (0.41--4.25)
  Western          1          112                  2.57 (1.28--5.16)                                          
  **CC + CA/AA**                                                                                              
  OS               Asian      1                    372                                                        0.70 (0.41--1.19)
  Western          4          1,576                1.21 (0.94--1.56)[\*](#jgm3114-note-0012){ref-type="fn"}   
  PFS              Asian      1                    81                                                         0.69 (0.39--1.23)
  Western          1          331                  0.87 (0.54--1.41)                                          
  DFS              Asian      1                    372                                                        0.92 (0.55--1.54)
  Western          --         --                   --                                                         
  **CA/AA**                                                                                                   
  OS               Asian      2                    783                                                        0.94 (0.68--1.28)
  Western          4          1,766                0.98 (0.83--1.16)                                          
  PFS              Asian      --                   --                                                         --
  Western          2          312                  0.97 (0.60--1.57)                                          
  DFS              Asian      1                    372                                                        0.89 (0.52--1.53)
  Western          2          884                  0.88 (0.72--1.09)                                          

--, Not available.

Results from the random‐effects model.

4. DISCUSSION {#jgm3114-sec-0015}
=============

Our meta‐analysis highlighted the long‐term prognostic effects (including OS, PFS and DFS) of *MTHFR* polymorphisms on patients with CRC. The rs1801131 polymorphism may predict the prognosis. Compared with patients with the CA + AA genotypes, patients with the CC genotype had a shorter OS (HR = 1.85) and DFS (HR = 2.15). However, significant differences were not observed among the other comparisons (CC versus AA, CC + CA versus AA and CA versus AA). Other researchers also reported similar results. For example, rs1801131 appears to be a potential prognostic factor for patients with gastric cancer.[13](#jgm3114-bib-0013){ref-type="ref"}, [44](#jgm3114-bib-0044){ref-type="ref"}, [45](#jgm3114-bib-0045){ref-type="ref"}

The *MTHFR* rs1801131 polymorphism may predict the prognosis; the possible explanations are described below. As a crucial enzyme in metabolism, MTHFR catalyses the transformation of 5,10‐MTHF into 5‐MTHF.[25](#jgm3114-bib-0025){ref-type="ref"}, [46](#jgm3114-bib-0046){ref-type="ref"}, [47](#jgm3114-bib-0047){ref-type="ref"}, [48](#jgm3114-bib-0048){ref-type="ref"} Notably, 5,10‐MTHF mainly synthesizes purines and thymidine. Furthermore, 5‐MTHF participates in the synthesis of *S*‐adenosyl‐methionine, which is an important mediator of methylation reactions.[47](#jgm3114-bib-0047){ref-type="ref"}, [48](#jgm3114-bib-0048){ref-type="ref"} Regarding rs1801131, its mutation is linked to reduced MTHFR enzyme activity, although the decrease is less pronounced than the change induced by 677CNT.[49](#jgm3114-bib-0049){ref-type="ref"} Therefore, the reduction in MTHFR enzyme activity as a result of the rs1801131 polymorphism may lead to a higher level of the precursor 5,10‐MTHF and a correspondingly lower level of 5‐MTHF, given the relatively low catalytic activity of the enzyme. The accumulation of 5,10‐MTHF would provide a greater pool of nucleotides for DNA synthesis, thus prompting tumour cell proliferation, which requires an abundant supply of nucleic acids. Once CRC has developed, folate supplementation might enhance its growth and progression,[42](#jgm3114-bib-0042){ref-type="ref"}, [48](#jgm3114-bib-0048){ref-type="ref"}, [50](#jgm3114-bib-0050){ref-type="ref"}, [51](#jgm3114-bib-0051){ref-type="ref"} presumably by providing large amounts of nucleotide precursors for tumour growth.[42](#jgm3114-bib-0042){ref-type="ref"}, [48](#jgm3114-bib-0048){ref-type="ref"}, [51](#jgm3114-bib-0051){ref-type="ref"} Folate supplementation is associated with a higher risk of CRC.[52](#jgm3114-bib-0052){ref-type="ref"} These findings indicate a negative effect of high levels of MTHFR on patients with CRC. Therefore, the association between *MTHFR* polymorphisms and a worse prognosis of CRC may be ascribed to decreased MTHFR activity.

In the present study, data heterogeneity was not observed; therefore, all of the data were analysed using fixed‐effects models. Subgroup analysis was performed according to the patient\'s nationality and revealed that rs1801133 and rs1801131 exerted the same effects on patients from Asian regions and patients from Western regions.

The *MTHFR* rs1801131 polymorphism may be associated with the prognosis of patients with CRC. In the future, additional high‐quality prospective studies should be conducted to obtain a better understanding of the prognostic value of the *MTHFR* polymorphisms. The *MTHFR* rs1801131 polymorphism may be regarded as a target for drugs that are widely used to treat cancer and inflammatory diseases.[12](#jgm3114-bib-0012){ref-type="ref"} This polymorphism may better predict the prognosis of patients with CRC and facilitate the administration of individualized treatments.

Some limitations exist in this meta‐analysis. (i) The eligible articles included in our meta‐analysis were restricted to studies published in English and Chinese, which likely caused selection bias. Articles published in other languages were excluded, which might cause selection bias as a result of low reporting qualities. (ii) The therapy method substantially affected the survival of patients with CRC. Although all of the included patients with CRC were treated with 5‐FU chemotherapy, the use of specific therapies differed among the included articles. Thus, the confounding effects of different therapies remain unclear. (ii) HRs calculated from the data or extracted from survival curves may be less reliable than HRs directly calculated with an analysis of variance.

In summary, the *MTHFR* rs1801133 polymorphism was not associated with the OS, PFS or DFS of patients with CRC. However, the *MTHFR* rs1801131 polymorphism was associated with a shorter OS and DFS in patients with CRC (CC + CA versus AA), although the other genotypes of *MTHFR* rs1801131 did not produce significant differences. Both rs1801133 and rs1801131 produced similar results among patients with CRC from Asian regions and Western regions. These results might provide guidance and prognostic predictive power for physicians during the clinical treatment of patients with CRC who are undergoing 5‐FU chemotherapy. Well‐designed prospective studies are necessary to further investigate the precise prognostic value of the *MTHFR* rs1801133 and rs1801131 polymorphisms.
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